ExpreS2ion Biotech Holding AB (publ) (EXPRS2) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

to today's event where we have the pleasure to present Expression Biotech. So that was today's presentation. We are joined by CEO Ben Fransen. Today's topic, of course, the Q1 results, but I think maybe more the news flow that you have have sent out in this quarter and actually also rather large snoops after the quarter's end. So I think that will be the main focus of today's events. As always, you can ask questions in the box down below. We have already got a lot in advance, but do feel free to ask him. Do feel free to ask him in Danish, and I will try and translate to the best of my ability. But for now, I will hand the call over to you, Bent. Thank you, Michael. My name is Bent Fransen. I'm the CEO of Expression Biotech. i'm pleased to be reviewing the status of our company in business and pipeline today may 15 in connection with the release of our interim report for q1 so the agenda for this meeting i'll first go through our strategic and financial review, you will notice that Keith Alexander, our CFO, is not present today. As usual, he is out on some travel commitments. Then I'll cover the ESOP C001 or therapeutic breast cancer program and where that is, and then the remaining pipeline with respect to infectious diseases before we go through Q&A here. so as a starting point just to highlight where we are with respect to our strategic focus so as you know expression is a vaccine focused company with a pipeline of cancer immunotherapies and infectious diseases vaccine projects and we have focused our strategic areas across four different areas here as highlighted here on our pipeline it's a key focus to progress on our esvb c001 of therapeutic breast cancer vaccine and i'll go into this in detail later in this presentation secondly we have a couple of very importa...